For the year ending 2025-12-31, RIGL has $513,594K in assets. $122,114K in debts. $40,580K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 40,580 | |||
| Short-term investments | 114,375 | |||
| Accounts receivable, net | 51,763 | |||
| Inventories | 11,506 | |||
| Prepaid and other current assets | 21,942 | |||
| Total current assets | 240,166 | |||
| Intangible assets, net | 24,748 | |||
| Deferred income tax asset | 245,852 | |||
| Operating lease right-of-use assets | 920 | |||
| Other assets | 1,908 | |||
| Total assets | 513,594 | |||
| Accounts payable | 7,191 | |||
| Accrued compensation | 11,914 | |||
| Accrued research and development | 5,524 | |||
| Acquisition related liabilities | 5,000 | |||
| Revenue reserves and refund liability | 27,716 | |||
| Loans payable, net, current portion | 29,812 | |||
| Other current liabilities | 11,466 | |||
| Lease liabilities, current portion | 614 | |||
| Total current liabilities | 99,237 | |||
| Acquisition-related liabilities | 0 | |||
| Long-term portion of lease liabilities | 395 | |||
| Long-term portion of loans payable, net | 22,482 | |||
| Other long-term liabilities | 0 | |||
| Total liabilities | 122,114 | |||
| Common stock, 0.001 par value 400,000,000 shares authorized 18,310,934 and 17,710,216 shares issued and outstanding as of december 31, 2025 and 2024, respectively | 18 | |||
| Additional paid-in capital | 1,414,322 | |||
| Accumulated other comprehensive income | 181 | |||
| Accumulated deficit | -1,023,041 | |||
| Total stockholders equity | 391,480 | |||
| Total liabilities and stockholders equity | 513,594 | |||
RIGEL PHARMACEUTICALS INC (RIGL)
RIGEL PHARMACEUTICALS INC (RIGL)